Jesper Andersen, PhD, associate professor, Biotech and Innovation Centre, University of Copenhagen, discusses the challenges facing the future treatment of patients with cholangiocarcinoma.
Jesper Andersen, PhD
Advertisement
Articles by Jesper Andersen, PhD
Jesper Andersen, PhD, associate professor, Biotech and Innovation Centre, University of Copenhagen, discusses the relationship between reduced organic cation transporter-1 (OCT1) and poor response to sorafenib (Nexavar) in hepatocellular carcinoma (HCC) and cholangiocarcinoma.
Advertisement
Latest Updated Articles
Relationship Between OCT1 Expression and Poor Response to Sorafenib in HCCPublished: April 21st 2017 | Updated:
Challenges Facing the Future of CholangiocarcinomaPublished: May 19th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5